Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
27.05
+0.07 (0.26%)
Dec 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 26.40 - 27.85
52 week 19.31 - 28.48
Open 26.98
Vol / Avg. 706,975.00/200,134.00
Mkt cap 1.02B
P/E 59.16
Div/yield     -
EPS 0.46
Shares 37.55M
Beta 1.07
Inst. own 78%
Mar 4, 2015
Q4 2014 Emergent BioSolutions Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
Emergent BioSolutions Inc at Oppenheimer Healthcare Conference - Webcast
Nov 11, 2014
Emergent BioSolutions Inc at Credit Suisse Healthcare Conference
Nov 6, 2014
Q3 2014 Emergent BioSolutions Inc Earnings Call - Webcast
Nov 6, 2014
Q3 2014 Emergent BioSolutions Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 15.83% 9.68%
Operating margin 22.49% 13.69%
EBITD margin - 20.64%
Return on average assets 10.26% 5.08%
Return on average equity 17.50% 6.69%
Employees 1,353 -
CDP Score - -

Address

SUITE 400, 2273 RESEARCH BLVD
ROCKVILLE, MD 20850
United States - Map
+1-301-7951800 (Phone)
+1-301-7951899 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and BioSciences Division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD). In August 2013, Emergent Biosolutions Inc closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. In February 2014, the Company acquired Cangene Corporation.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Daniel J. Abdun-Nabi President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Chief Financial Officer, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer
Age: 56
Bio & Compensation  - Reuters
Anatolio B. Cruz III Executive Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Adam Havey Executive Vice President, President - BioDefense Division
Age: 43
Bio & Compensation  - Reuters
Barry A. Labinger Executive Vice President, President - Biosciences Division
Age: 50
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 58
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
George A. Joulwan Independent Director
Age: 74
Bio & Compensation  - Reuters